Articles By Jack Cush, MD
EULAR 2020 - Top 5 Abstracts
In no particular order, these are my top 5 presentations from this year's EULAR 2020 meeting. Congratulations to EULAR for pulling off the educational coup of the year by transforming their world class gigantic Frankfurt meeting into a worldwide virtual meeting in less than 8 weeks – KUDOS!
Read Article
Virtual EULAR 2020 Round Up
In this week's podcast, Drs. Artie Kavanaugh and Jack Cush present highlights from the virtual EULAR2020 meeting held June 3-6, 2020. Featured reports include the SELECT-CHOICE study, the EXCEED trial, Avacopan in AAV, BeST mortality outcomes, BLISS-LN study, biosimilars and tofa in systemic sclerosis.
Read Article
Day 4 - Top 3 from EULAR 2020
These were my top abstracts from Thursday, 4th of June at EULAR 2020:
Read Article
Day 3 - Top 5 from EULAR 2020
These were my top abstracts from Thursday, 4th of June at EULAR 2020:
Read Article
Day 2 – Top 5 from EULAR 2020
These were my top abstracts from Thursday, 4th of June at EULAR 2020.
Read Article
RheumNow Podcast – The Future of JAKs (6.5.20)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read Article
Preventing COVID - Masks, Meters and Eyewear
A Lancet systematic review and meta-analysis provides the basis for physical distancing and the value of making as measures to prevent infection with coronavirus 2 (SARS-CoV-2) or COVID-19. The analysis included 172 observational studies, no randomised controlled trials and 44 relevant comparative studies involving 25 697 patients.
Read Article
Hydroxychloroquine Postexposure Prophylaxis for COVID-19 Fails
NEJM has reported that the use of hydroxychloroquine did not prevent symptomatic COVID-19 infection when used within 4 days after SARS-CoV-2 exposure. Currently for persons who are COVID exposed, the standard of care is quarantine and there is no known preventative therapy.
Read Article
TNR Grand Rounds - Update on Biosimilars
This week's Tuesday Nite Rheumatology featured Dr Jonathan Kay (U Mass) who gave an update on Biosimilars and took questions the subject. The program was moderated by Dr. Jack Cush.
Read Article
